Benign Airway Stenosis, Respiratory Tract Fistula
Conditions
Keywords
Stromal Vascular Fraction
Brief summary
Benign airway stenosis and respiratory tract fistula are common types of airway injury. The diseases occurred after endogenous and exogenous stimuli (tuberculosis, tumor, surgery, tracheal intubation) causing damage to the airway mucosa, resulting in scar repair and irreversible loss of airway epithelium. Autologous adipose vascular fraction (stromal vascular fraction, SVF) is a mixture of cells obtained from adipose tissue through digestion and centrifugation, containing a variety of cell types, such as mesenchymal cells, endothelial progenitor cells, endothelial cells, pericytes, and macrophages. Previous studies have shown that SVF can achieve regeneration and wound healing through modulating the immune microenvironment, promoting angiogenesis, thereby promoting endogenous regeneration of the in situ adult stem cells. This project utilizes the tissue repair function of autologous SVF to treat benign airway stenosis and respiratory tract fistula. To clarify the efficacy and safety of autologous SVF in the treatment of airway injury.
Interventions
PROCEDUREControl group
Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
PROCEDURESVF group
SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula
Sponsors
Guangzhou Institute of Respiratory Disease
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Subjects aged between 18 to 75 * Subjects diagnosed with benign airway stenosis, tracheoesophageal fistula(the sizes of the fistulas less than 2cm), and bronchopleural fistula * Subjects willing to accept SVF treatment * Subjects tolerant to the bronchoscope * Subjects signed informed consent
Exclusion criteria
* Subjects with the following pulmonary diseases: asthma, active pulmonary tuberculosis, pulmonary embolism, pneumothorax, pulmonary hypertension, etc; * Subjects with incomplete remission of malignant tumors or with incurable malignant tumors; * Subjects with uncontrolled systemic infection; * Subjects requiring anti-clotting drugs; * Subjects with myocardial infarction, unstable angina, liver cirrhosis, acute glomerulonephritis, etc; * Subjects with syphilis, HIV, HBV, HCV antibody positive; * Subjects with Coagulation disorders such as hemophilia, giant platelet syndrome, thromboasthenia, etc; * Subjects with severe renal damage, serum creatinine is more than 1.5 times the upper limit of the normal value; * Subjects with liver disease or liver damage: ALT, AST, total bilirubin \> 2 times the upper limit of the normal value; * Subjects with a history of psychosis or suicide or epilepsy or other central nervous system diseases; * Subjects with severe arrhythmias(e.g. ventricular tachycardia, frequent supraventricular tachycardia, atrial fibrillation, atrial flutter, etc.) or degree II above abnormal conduction; * Subjects allergic to thrombin; * Subjects accepted by any other clinical study within the first three months of the study; * Subjects with poor compliance; * Any other conditions might increase the risk of the patient or interfere with the clinical study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cure rate for benign airway stenosis | within 3 months after administration | The proportion of patients who is no need for endotracheal intervention and with stable clinical symptoms after SVF treatment |
| Cure rate for respiratory tract fistula | within 3 months after administration | The proportion of patients who have complete closure of fistula, no need for endotracheal intervention and with stable clinical symptoms after SVF treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical complete remission time | within 3 months after administration | The interval time of the first intratracheal interventional therapy needed again after SVF treatment |
| Times of unplanned treatment | within 3 months after administration | The number of times a patient needs to be reviewed and treated by bronchoscopy |
| Incidence of complications associated with SVF treatment | within 3 months after administration | Wound healing, sputum retention, etc. during follow-up |
Countries
China
Contacts
Primary ContactShiyue Li, MD
Backup ContactXinyu Song, MD
Outcome results
None listed